← Back to Search

Vitamin

Nicotinamide Riboside for Sarcopenia (NR-VET Trial)

N/A
Recruiting
Led By Kenneth L Seldeen, PhD
Research Sponsored by VA Office of Research and Development
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Male or female
Ages 65-85
Timeline
Screening 3 weeks
Treatment Varies
Follow Up change from baseline to endpoint at 12 weeks
Awards & highlights

NR-VET Trial Summary

This trial will test whether nicotinamide riboside, a form of vitamin B3, is safe and effective in improving muscle function and physiology in humans.

Who is the study for?
This trial is for older veterans aged 65-85 who can use an exercise bike and are medically cleared for a muscle biopsy. It's not suitable for individuals with severe illnesses, advanced heart failure or COPD, serious kidney disease, significant cognitive impairment, or those extremely overweight.Check my eligibility
What is being tested?
The study tests if Nicotinamide Riboside (a vitamin B3 form) can improve muscle function and increase NAD+ levels in the body compared to a placebo. Participants will be randomly assigned to either the supplement group or placebo group without knowing which one they're receiving.See study design
What are the potential side effects?
Nicotinamide Riboside is generally considered safe based on previous human trials; however, potential side effects are not detailed in this summary. Typically, vitamin supplements may cause mild issues like nausea or headaches.

NR-VET Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am either male or female.
Select...
I am between 65 and 85 years old.
Select...
I am cleared by a doctor to have a muscle biopsy.

NR-VET Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~change from baseline to endpoint at 12 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and change from baseline to endpoint at 12 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Gait speed
Maximal oxygen uptake test (VO2max)
Muscle strength
Secondary outcome measures
Body Composition (Lean and fat mass)
Cognitive screen
Frailty assessment
+4 more

NR-VET Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: NR SupplementationExperimental Treatment1 Intervention
Participants in this group will receive NR supplementation at 1000 mg per day (given as 2x250mg capsules morning and 2x250mg at night).
Group II: Placebo supplementationPlacebo Group1 Intervention
Participants in this group will receive placebo given as 2 pills in the morning and 2 pills at night. Placebo pills contain micro cellulose which is likewise found in NR containing capsules.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Nicotinamide Riboside
2022
N/A
~160

Find a Location

Who is running the clinical trial?

University at BuffaloOTHER
131 Previous Clinical Trials
98,815 Total Patients Enrolled
VA Office of Research and DevelopmentLead Sponsor
1,607 Previous Clinical Trials
3,305,891 Total Patients Enrolled
3 Trials studying Sarcopenia
255 Patients Enrolled for Sarcopenia
Kenneth L Seldeen, PhDPrincipal InvestigatorKansas City VA Medical Center, Kansas City, MO

Media Library

Nicotinamide Riboside (Vitamin) Clinical Trial Eligibility Overview. Trial Name: NCT04691986 — N/A
Sarcopenia Research Study Groups: NR Supplementation, Placebo supplementation
Sarcopenia Clinical Trial 2023: Nicotinamide Riboside Highlights & Side Effects. Trial Name: NCT04691986 — N/A
Nicotinamide Riboside (Vitamin) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04691986 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is the age limit for trial enrollment beyond thirty years of age?

"This research is open to senior citizens aged between 65 and 85."

Answered by AI

Does this experiment have any open slots for participants?

"According to the information posted on clinicaltrials.gov, this study is no longer open for applicants. It was first announced on January 15th 2023 but has since been edited as of November 8th 2022 and closed off recruitment. Nonetheless, there are currently 105 other trials actively looking for participants right now."

Answered by AI

What objectives are being pursued with this clinical experiment?

"This clinical trial will be evaluated over a 12-week period, with the goal of measuring maximal oxygen uptake (VO2max). Secondary outcomes include body composition assessed through bioelectric impedance (BIA), muscle analysis including NAD+ content and mitochondrial health, messageRNA expression changes in response to treatment, and quality of life assessment using the Quality of Life Enjoyment & Satisfaction Questionnaire - Short Form (Q-LES-Q-SF) survey instrument."

Answered by AI

Am I eligible for entry into this research program?

"To qualify for this trial, prospective participants must meet the following criteria: Gender (male or female), Capacity to cycle on a stationary bike, Age range of 65-85 years old and No racial restriction. Ultimately, 144 people with sarcopenia are being sought."

Answered by AI
~96 spots leftby Mar 2025